The transcriptomic analysis revealed a significant decrease in RCOR2 mRNA expression in melanoma from patients who achieved a partial or complete response to anti–PD-1 ICB, as compared with those who did not respond to the treatment (Figure 9A). This evidence concerns the gene RCOR2 and melanoma.